Truvestments Capital LLC bought a new position in shares of Clorox Co (NYSE:CLX) during the first quarter, Holdings Channel reports. The institutional investor bought 255 shares of the company’s stock, valued at approximately $41,000.
Several other hedge funds and other institutional investors have also made changes to their positions in CLX. JPMorgan Chase & Co. increased its holdings in Clorox by 5.2% in the third quarter. JPMorgan Chase & Co. now owns 1,019,248 shares of the company’s stock valued at $153,305,000 after buying an additional 50,360 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Clorox by 15.1% in the third quarter. Bank of New York Mellon Corp now owns 1,664,803 shares of the company’s stock valued at $250,403,000 after buying an additional 218,364 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in Clorox by 16.1% in the third quarter. Allianz Asset Management GmbH now owns 23,996 shares of the company’s stock valued at $3,609,000 after buying an additional 3,319 shares during the last quarter. Pacer Advisors Inc. increased its holdings in Clorox by 18.7% in the third quarter. Pacer Advisors Inc. now owns 7,037 shares of the company’s stock valued at $1,058,000 after buying an additional 1,108 shares during the last quarter. Finally, Man Group plc increased its holdings in Clorox by 123.9% in the third quarter. Man Group plc now owns 14,578 shares of the company’s stock valued at $2,193,000 after buying an additional 8,066 shares during the last quarter. 76.90% of the stock is currently owned by institutional investors and hedge funds.
CLX has been the subject of several recent research reports. Zacks Investment Research lowered Clorox from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Barclays reaffirmed a “hold” rating and set a $142.00 target price on shares of Clorox in a report on Wednesday, February 6th. Credit Suisse Group initiated coverage on Clorox in a report on Wednesday, March 6th. They set an “outperform” rating and a $172.00 target price for the company. Wells Fargo & Co reaffirmed a “hold” rating and set a $157.00 target price on shares of Clorox in a report on Thursday, February 21st. Finally, BMO Capital Markets set a $175.00 target price on Clorox and gave the company a “buy” rating in a report on Tuesday, February 5th. Six equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $151.21.
Clorox (NYSE:CLX) last issued its quarterly earnings data on Monday, February 4th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.08. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The business’s revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.77 earnings per share. On average, analysts predict that Clorox Co will post 6.31 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Wednesday, April 24th will be given a $0.96 dividend. The ex-dividend date is Tuesday, April 23rd. This represents a $3.84 dividend on an annualized basis and a yield of 2.52%. Clorox’s dividend payout ratio (DPR) is 61.34%.
In other Clorox news, SVP Andrew J. Mowery sold 5,340 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $156.44, for a total value of $835,389.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Matthew T. Laszlo sold 10,585 shares of the company’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total value of $1,628,925.65. Following the completion of the sale, the senior vice president now owns 17,994 shares of the company’s stock, valued at $2,769,096.66. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Recommended Story: Diversification
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.